The Seven Miracles
Nobody's Pricing In

In February 2025, doctors at Children's Hospital of Philadelphia treated an infant with a rare enzyme deficiency using a bespoke CRISPR base-editing therapy designed, manufactured, and delivered in just six months. Not a clinical trial. Not a mass-market drug. A medicine built for exactly one human being.

This isn't incremental. This is the moment medicine shifts from "find the drug that fits your disease" to "build the drug that fits you." There are ~7,000 known rare genetic diseases affecting 300 million people worldwide. Most have zero treatments. A Center for Pediatric CRISPR Cures launched in California in 2025, and the FDA created a new regulatory pathway specifically for these one-of-one therapies.

The second-order effects are enormous: if you can design a genetic fix in six months for one patient, what happens when AI cuts that to six weeks? What happens when it costs $50K instead of $500K? The pharmaceutical industry's entire batch-manufacturing model breaks.

Form Energy's iron-air battery passed UL safety certification in late 2024 and began manufacturing at scale in 2025. Orders from Xcel Energy and Georgia Power are going live in 2025-2026. The core chemistry is reversible rusting — iron oxidizes to store energy, de-oxidizes to release it. The materials are the three most abundant things on Earth: iron, water, and air.

Why this matters more than people think: lithium-ion batteries can store ~4 hours of grid energy. That's fine for smoothing solar dips. But to survive a 3-day winter storm with no sun or wind, you need 100-hour storage. That's always been the missing piece for a fully renewable grid. Iron-air solves it — at roughly 1/10th the cost of lithium per kWh for long duration.

The elegance: iron doesn't catch fire (it passed UL9540A with no flame, no thermal runaway). It doesn't require cobalt mines in the Congo or lithium brines in Chile. It's just... rust.

In 2025, xenotransplantation went from "interesting experiment" to "this actually works." A kidney from a 69-gene-edited pig functioned for 271 days in a human recipient — shattering every previous record. Multiple compassionate-use cases followed. Science magazine named it their Breakthrough of the Year.

The scale of the problem: 103,000 people are on the U.S. organ transplant waiting list right now. 17 die every day waiting. The entire transplant system is bottlenecked by supply — there are never enough human donors. Gene-edited pig organs turn this from a scarcity problem into a production problem. And production problems are solvable.

The gene editing required is extraordinary — removing pig viruses, adding human compatibility genes, knocking out rejection triggers. This is CRISPR's industrial application: not fixing one gene in one patient, but rewriting an entire species to be compatible with ours.

This is the one that sounds the craziest — and it's the one that's actually happening. Colossal Biosciences (based in Texas, backed by $225M+) has fully sequenced the woolly mammoth genome and is using CRISPR to engineer Asian elephant cells with mammoth cold-adaptation traits: thick fat layers, small ears, shaggy hair, hemoglobin that works at -40°.

In July 2025, they announced a collaboration with Peter Jackson (yes, the Lord of the Rings director) and New Zealand institutions to de-extinct the moa. They're working on dodo restoration, dire wolves, thylacines, and — this is real — Irish elk, saber-tooth cats, and woolly rhinoceros.

The actual scientific breakthrough isn't the mammoth. It's that Colossal has built a species-restoration platform — a repeatable process for reading an extinct genome and writing its traits into a living relative. They expect to de-extinct additional species before 2028. The mammoth is the proof of concept. The platform is the product.

BCIs won MIT Technology Review's "11th Breakthrough" vote by a landslide in 2025. Over $1.3 billion flowed into neurotech in 2025 alone, led by Neuralink's $650M round. Multiple patients are now controlling cursors, typing, and browsing the internet using only brain signals.

But the real frontier is Blindsight — Neuralink's second device, which bypasses damaged eyes entirely and sends visual information directly to the brain's visual cortex. It received FDA Breakthrough Device Designation in 2025, with human trials expected late 2025 or early 2026. If it works, it means sight — actual sight — for people who have none.

The trajectory: today it's for paralysis and blindness. In 10 years, the question becomes: why would anyone type when they can think? The mouse, the keyboard, the touchscreen — all of them are translators between thought and action. BCIs remove the translator.

In October 2025, the U.S. Department of Energy released the first-ever Fusion Science & Technology Roadmap — a formal national strategy to commercialize fusion energy. This isn't a research wish-list. It's a roadmap with milestones, timelines, and allocated resources.

Helion Energy (backed by Sam Altman) achieved fusion with its Polaris prototype in 2024 and is targeting 50 MW net output in 2026. They already have a power purchase agreement with Microsoft. Commonwealth Fusion Systems in the UK holds 15 patents on compact fusion designs and is negotiating PPAs with EDF.

What changed: high-temperature superconducting magnets. They allow much smaller, much cheaper fusion reactors. What used to require a building the size of an aircraft carrier might now fit in a warehouse. The physics was always sound — the engineering just finally caught up.

Synthetic biology hit an inflection in 2025. At iGEM (the world's largest synthetic biology competition), the Grand Prize went to a team that engineered duckweed — a common pond plant — into a plastic-digesting organism. Nature published a platform for microbial conversion of end-of-life plastics into fuels and biopolymers.

The concept: take a microbe, reprogram its DNA like software, and tell it to eat something toxic and excrete something useful. Plastic waste becomes jet fuel. Agricultural runoff becomes bioplastics. CO₂ becomes protein.

This is biology becoming an engineering discipline. The tools now exist to design biological circuits (if X, then Y), build programmable immune responses, and create organisms that have never existed in nature. We're writing life from scratch — not as a metaphor, but literally, nucleotide by nucleotide. The first fully synthetic bacterial genome was built in 2010. By 2026, teams are building synthetic genomes to create entirely new life forms.